The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes patients.

The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

The case for Ozempic as a dementia buster is building. Research published this week has found that GLP-1 drugs are associated with a lower risk of dementia in people with type 2 diabetes.

Ozempic and similar novel diabetes treatments may lower the risk of Alzheimer's disease and related dementias.. This is the conclusion of a pair of studies by research teams from the U.S. and ...

Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the secret to staving off Alzheimer’s, too.

“In November 2022, a study revealed that blood pressure drugs that stimulate type 2 and 4 angiotensin II receptors in the brain were associated with lower rates of dementia among new users of ...

Study links 'bad cholesterol' to dementia. Reducing levels of LDL-cholesterol can reduce the risk of dementia by 26%, and statins could add to the benefit, according to a just-published study.